Hoth Therapeutics pulls in $3 mln Series A
New York City-based Hoth Therapeutics, a biopharmaceutical company focused on treating patients suffering from ailments such as atopic dermatitis, has raised $3 million in Series A funding. The investors were not named. Laidlaw & Co (UK) Ltd was the placement agent.
22 February 2018•2 mins read
